Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-26-126410

Chief Development Officer sold 10,115 shares at $29.99 ($303,355)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Yeleswaram Krishnaswamy Chief Development Officer 2026-03-25 Sale 10b5-1 −10,115 $29.99 $303,355 286,876 D: show line 1 in the form
Open-market sales · 10,115 sh · avg $29.99 · $303,355
Loading xslF345X06/ownership.xml…